These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. ASSENT-3: implications for future trial design and clinical practice. Van de Werf F Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439 [No Abstract] [Full Text] [Related]
26. Optimizing outcomes in ST-segment elevation myocardial infarction. Herrmann HC J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574 [No Abstract] [Full Text] [Related]
27. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542 [TBL] [Abstract][Full Text] [Related]
28. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737 [TBL] [Abstract][Full Text] [Related]
29. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction. Martinez-Ojeda J; Martinez-Toro J Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071 [TBL] [Abstract][Full Text] [Related]
30. Rescue percutaneous coronary intervention after failed thrombolysis: results from the Acute Coronary Syndrome Israel Surveys (ACSIS). Yalonetsky S; Gruberg L; Sandach A; Hammerman H; Beyar R; Hod H; Behar S Acute Card Care; 2006; 8(2):83-6. PubMed ID: 16885071 [TBL] [Abstract][Full Text] [Related]